Back to Alzheimers Disease
NCT00151398
NCT00151398
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with probable Alzheimer's disease based on standard medical criteria.
- You are able to give your own consent to take part, and your caregiver must also agree to participate in the study.
Who may not be able to join:
- You have taken any medications aimed at improving memory or thinking within the 3 months before the study starts.
- You have another significant brain or nervous system condition (other than Alzheimer's disease) that could affect your thinking or memory.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 2
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Registry
clinicaltrials_gov
Start date
6 October 2005
Est. completion
15 March 2008
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇨🇦 Canada
🇿🇦 South Africa
🇺🇸 United States
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
The primary endpoints will be the change from baseline in ADAS-Cog total score and ADCS-CGIC total score.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.